3B Blackbio DX Share Price Today (3BBLACKBIO)
TODAY IN ONE LINE
3BBLACKBIO fell 1.4%, lagging Nifty's 1.1% move, supported by recent strong earnings.
With a market cap of ₹1,073.35 Cr., it trades at a P/E of 17.11. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
3B Blackbio DX scorecard
Overall performance across 5 key dimensions.
3B Blackbio DX flags
Key strengths and potential risks.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 57.5% and Profit up 13.8%
- ●High Capital EfficiencyROCE of 25.5% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 19.8%
- ●Healthy Operating MarginsOPM is structurally strong at 40.0%
- ●Reasonable ValuationTrading at a moderate P/E of 17.1x
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
What changed recently?
Recent events, corporate actions, and announcements.
3B Blackbio DX Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for 3B Blackbio DX Ltd, framed against the sector median so the premium or discount is obvious at a glance.
3B Blackbio DX Ltd trades at a P/E of 17.11× and P/B of 3.09×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
3B Blackbio DX Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for 3B Blackbio DX Ltd — derived from the live tape, not yesterday's close.
3B Blackbio DX Ltd last traded at ₹1,250.4 with an intraday range of ₹1,240–₹1,276.1 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1250.40| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1343.20 | +92.80 | +7.42% |
| R3 | 1307.10 | +56.70 | +4.53% |
| R2 | 1291.60 | +41.20 | +3.29% |
| R1 | 1271.00 | +20.60 | +1.65% |
| PIVOT | 1255.50 | 5.10 | 0.41% |
| CURRENT | 1250.40 | — | — |
| S1 | 1234.90 | -15.50 | -1.24% |
| S2 | 1219.40 | -31.00 | -2.48% |
| S3 | 1198.80 | -51.60 | -4.13% |
| S4 | 1162.70 | -87.70 | -7.01% |
3BBLACKBIO is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹1253.2–₹1276.1
Trading Inside opening range
3B Blackbio DX Ltd financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for 3B Blackbio DX Ltd — consolidated or standalone — with margins, YoY growth and key ratios inline.
3B Blackbio DX Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,073.35 Cr. and reported EPS of ₹68.30.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 96 | 142 ▲ 47.1% |
| Sales Growth YoY %Derived | 30.14% | 47.11% |
| Other Income | 15 | 26 ▲ 69.4% |
| Total Income | 112 | 167 ▲ 50.1% |
| 26 | 36 ▲ 39.8% | |
| Gross ProfitDerived | 71 | 106 ▲ 49.8% |
| Gross Margin %Derived | 73.42% | 74.74% |
| 21 | 49 ▲ 137.9% | |
| EBITDA (Operating Profit)Derived | 50 | 57 ▲ 13.3% |
| OPM %Derived | 51.94% | 40.00% |
| 1 | 5 ▲ 349.0% | |
| Profit Before Tax (PBT) | 64 | 77 ▲ 20.3% |
| 16 | 17 ▲ 4.5% | |
| Effective Tax %Derived | 25.48% | 22.14% |
| Total Profit for Period | 48 | 60 ▲ 25.7% |
| Less: Non-controlling Interests | 0 | 1 ▲ 3302.3% |
| Net Profit (Owner's PAT)Derived | 48 | 59 ▲ 22.9% |
| Net Profit Margin %Derived | 49.40% | 41.28% |
| PAT Growth YoY %Derived | 45.57% | 22.95% |
| Earnings Per Share (EPS ₹) | 55.52 | 68.26 ▲ 22.9% |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | — | — |
| Total Expenses (incl. D&A & Interest) | 48 | 91 ▲ 90.3% |
| Material Cost % of RevenueDerived | 26.96% | 25.18% |
| Employee Cost % of RevenueDerived | 7.59% | 16.89% |
| Other Cost % of RevenueDerived | 13.88% | 17.84% |
| Interest Coverage (x)Derived | 451.83x | 217.84x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 23 | 29 ▲ 24.0% | 227 ▲ 685.3% | 81 ▼ 64.4% | 62 ▼ 23.3% | 74 ▲ 19.9% | 96 ▲ 30.1% | 142 ▲ 47.1% | |
| Sales Growth YoY %Derived | — | 24.05% | 685.26% | -64.43% | -23.32% | 19.87% | 30.14% | 47.11% | |
| Other Income | 1 | 2 ▲ 115.7% | 3 ▲ 80.8% | 7 ▲ 138.7% | 7 ▲ 4.7% | 13 ▲ 73.4% | 15 ▲ 20.4% | 26 ▲ 69.4% | |
| Total Income | 24 | 30 ▲ 26.9% | 230 ▲ 653.5% | 88 ▼ 61.9% | 69 ▼ 21.1% | 87 ▲ 25.5% | 112 ▲ 28.7% | 167 ▲ 50.1% | |
11 | 13 ▲ 22.4% | 52 ▲ 288.9% | 32 ▼ 38.7% | 18 ▼ 43.3% | 22 ▲ 21.9% | 26 ▲ 17.4% | 36 ▲ 39.8% | ||
| Gross ProfitDerived | 12 | 16 ▲ 25.5% | 175 ▲ 1021.8% | 49 ▼ 72.0% | 44 ▼ 10.4% | 52 ▲ 19.0% | 71 ▲ 35.5% | 106 ▲ 49.8% | |
| Gross Margin %Derived | 53.47% | 54.08% | 77.26% | 60.79% | 71.03% | 70.53% | 73.42% | 74.74% | |
5 | 6 ▲ 20.5% | 25 ▲ 299.9% | 12 ▼ 52.6% | 15 ▲ 23.9% | 19 ▲ 30.6% | 21 ▲ 7.3% | 49 ▲ 137.9% | ||
| EBITDA (Operating Profit)Derived | 7 | 9 ▲ 29.1% | 150 ▲ 1509.7% | 37 ▼ 75.3% | 29 ▼ 21.4% | 33 ▲ 13.2% | 50 ▲ 51.9% | 57 ▲ 13.3% | |
| OPM %Derived | 31.02% | 32.27% | 66.15% | 46.00% | 47.13% | 44.49% | 51.94% | 40.00% | |
1 | 1 ▼ 13.3% | 1 ▼ 3.6% | 1 ▼ 7.9% | 1 ▲ 36.4% | 1 ▲ 11.3% | 1 ▲ 1.1% | 5 ▲ 349.0% | ||
| Profit Before Tax (PBT) | 7 | 10 ▲ 44.6% | 152 ▲ 1412.6% | 43 ▼ 71.6% | 35 ▼ 18.3% | 44 ▲ 25.6% | 64 ▲ 44.4% | 77 ▲ 20.3% | |
2 | 2 ▲ 38.3% | 38 ▲ 1514.3% | 11 ▼ 71.1% | 9 ▼ 15.0% | 12 ▲ 30.5% | 16 ▲ 33.3% | 17 ▲ 4.5% | ||
| Effective Tax %Derived | 24.60% | 23.52% | 25.10% | 25.50% | 26.54% | 27.59% | 25.48% | 22.14% | |
| Total Profit for Period | 5 | 8 ▲ 46.7% | 114 ▲ 1381.3% | 32 ▼ 71.7% | 26 ▼ 19.4% | 32 ▲ 23.8% | 48 ▲ 48.6% | 60 ▲ 25.7% | |
| Less: Non-controlling Interests | 0 | 1 ▲ 298.5% | 14 ▲ 1489.4% | 4 ▼ 71.6% | 3 ▼ 18.2% | -1 ▼ 119.4% | 0 ▲ 106.2% | 1 ▲ 3302.3% | |
| Net Profit (Owner's PAT)Derived | 5 | 7 ▲ 35.5% | 100 ▲ 1367.2% | 28 ▼ 71.7% | 23 ▼ 19.6% | 33 ▲ 44.4% | 48 ▲ 45.6% | 59 ▲ 22.9% | |
| Net Profit Margin %Derived | 21.56% | 23.55% | 44.01% | 34.97% | 36.66% | 44.16% | 49.40% | 41.28% | |
| PAT Growth YoY %Derived | — | 35.50% | 1,367.18% | -71.74% | -19.62% | 44.40% | 45.57% | 22.95% | |
| Earnings Per Share (EPS ₹) | 7.83 | 9.06 ▲ 15.7% | 132.91 ▲ 1367.0% | 37.56 ▼ 71.7% | 30.19 ▼ 19.6% | 38.14 ▲ 26.3% | 55.52 ▲ 45.6% | 68.26 ▲ 22.9% | |
| Diluted Shares Outstanding (Cr) | 1 | 1 ▲ 17.2% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 0.0% | 1 ▲ 14.3% | 1 ▲ 0.0% | 1 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | — | -0 | 0 ▲ 200.0% | — ▼ 100.0% | — | — | — | — | |
| Total Expenses (incl. D&A & Interest) | 17 | 20 ▲ 19.7% | 78 ▲ 280.0% | 44 ▼ 42.9% | 34 ▼ 23.9% | 42 ▲ 25.4% | 48 ▲ 12.4% | 91 ▲ 90.3% | |
| Material Cost % of RevenueDerived | 48.08% | 45.95% | 22.39% | 38.03% | 29.12% | 26.73% | 26.96% | 25.18% | |
| Employee Cost % of RevenueDerived | 10.89% | 9.86% | 2.06% | 4.42% | 8.13% | 8.77% | 7.59% | 16.89% | |
| Other Cost % of RevenueDerived | 11.57% | 11.95% | 9.05% | 10.37% | 15.76% | 17.27% | 13.88% | 17.84% | |
| Interest Coverage (x)Derived | 14.42x | 26.28x | 654.28x | 342.35x | 142.55x | 256.62x | 451.83x | 217.84x |
3B Blackbio DX segment analysis : revenue and profit mix.
Disclosed business segments at 3B Blackbio DX with their share of revenue and profit, switchable between consolidated and standalone reporting.
3B Blackbio DX discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for 3B Blackbio DX Ltd.
Our AI distills the core fundamental drivers supporting 3B Blackbio DX Ltd, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 22 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 15% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.17%.
3B Blackbio DX Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — 3B Blackbio DX Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
3B Blackbio DX Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for 3B Blackbio DX Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
3B Blackbio DX Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for 3B Blackbio DX Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in 3B Blackbio DX Ltd stood at 65.8% of traded volume, against a 20-day average of 56.7%.
3B Blackbio DX announcements: results, concalls, ratings, M&A.
Filings 3B Blackbio DX sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
3B Blackbio DX files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 81 documents below.
Company Update
Special Window for Re-lodgement of Transfer Requests of physical shares
Company Update
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
Company Update
Newspaper Publication for Transfer of Unclaimed Dividend/Equity Shares to IEPF Authority
Insider Trading / SAST
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for…
Company Update
Disclosure under Regulation 29 (2) of SEBI (SAST) Regulations, 2011
Investor decks & rating reports.
3B Blackbio DX dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue 3B Blackbio DX has declared, sequenced by announce and record date.
3B Blackbio DX corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About 3B Blackbio DX Ltd: business, sector, key facts.
What 3B Blackbio DX Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
3B Blackbio DX Ltd is a listed Indian equity, listed as NSE: 3BBLACKBIO, BSE: 532067.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Abbott India (ABBOTINDIA) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- Anlon Healthcare (AHCL) Share PricePeer
- Amanta Healthcare (AMANTA) Share PricePeer
- Ambalal Sarabhai Enterprises (AMBALALSA) Share PricePeer
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top quality scorecard stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about 3B Blackbio DX Ltd (3BBLACKBIO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of 3B Blackbio DX Ltd (3BBLACKBIO)?
The current share price of 3B Blackbio DX Ltd (3BBLACKBIO) is ₹1,250.4. Today, the stock has declined by ₹18.10 (1.43%), trading in a range of ₹1,240 to ₹1,276.1. The stock opened at ₹1,269.3 with a trading volume of 18,231 shares.
02Is 3B Blackbio DX Ltd stock a good investment for long-term?
3B Blackbio DX Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,073.35 crores, P/E ratio of 17.11, ROE of 19.80%, and ROCE of 25.50%. The dividend yield stands at 0.34%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of 3B Blackbio DX Ltd stock?
The 52-week high price of 3B Blackbio DX Ltd (3BBLACKBIO) is ₹1,441.5, while the 52-week low is ₹1,085. Currently trading at ₹1,250.4, the stock is 46.4% away from its 52-week low and 13.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy 3B Blackbio DX Ltd stock at the current price?
Whether to buy 3B Blackbio DX Ltd stock at ₹1,250.4 depends on multiple factors. The stock is currently trading with a P/E ratio of 17.11 and P/B ratio of 3.09. Today's performance shows a loss of 1.43%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of 3B Blackbio DX Ltd and when is the next dividend?
3B Blackbio DX Ltd offers a dividend yield of 0.34%, which means for every ₹100 invested at the current price of ₹1,250.4, you can expect to receive approximately ₹0.34 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of 3B Blackbio DX Ltd?
3B Blackbio DX Ltd's key financial metrics include: P/E Ratio: 17.11, P/B Ratio: 3.09, ROE: 19.80%, ROCE: 25.50%, Dividend Yield: 0.34%, EPS: ₹68.30, Book Value: ₹378, and Debt-to-Equity: 0.01. The company's market cap stands at ₹1,073.35 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is 3B Blackbio DX Ltd stock performing today in the market?
3B Blackbio DX Ltd stock opened at ₹1,269.3 and is currently trading at ₹1,250.4, showing a decline of ₹18.10 (1.43%). The intraday high is ₹1,276.1 and low is ₹1,240. The trading volume stands at 18,231 shares, indicating moderate market participation today.
08What is the P/E ratio of 3B Blackbio DX Ltd and what does it indicate?
3B Blackbio DX Ltd has a Price-to-Earnings (P/E) ratio of 17.11, which means investors are willing to pay ₹17.11 for every ₹1 of earnings. With an EPS of ₹68.30, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about 3B Blackbio DX Ltd (3BBLACKBIO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.